Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
Collaboration expected to increase provider and patient access to potentially life-saving colorectal cancer screening that enables earlier disease…
Don Hardison Appointed Chairman of the Board at Geneoscopy
ST. LOUIS. MO – November 9, 2023 – Geneoscopy, a life sciences company focused on developing diagnostic tests for gastrointestinal health, has…
JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests
Geneoscopy’s noninvasive, multi-target, stool RNA (mt-sRNA) colorectal cancer screening test showed extraordinary sensitivity for detecting…
Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting
Company to Showcase Its Noninvasive RNA-based Technology Platform Designed to Improve Diagnostic Tools for Gastrointestinal Health ST LOUIS, MO –…
Geneoscopy appoints Don Hardison to its Board of Directors
ST. LOUIS, Feb. 28, 2023 /PRNewswire/ Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of…
Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test
FDA’s Decision Forthcoming for Innovative Test with Agency’s Breakthrough Device Designation ST LOUIS, Jan. 24, 2023 / — Geneoscopy, Inc., a…
